A PMTA asks FDA to allow a specific new tobacco product, including a vape, to be marketed in the United States.
The application is not the authorization. FDA must issue a written marketing granted order for the product before the order can serve as federal marketing authorization.
Review status: This guide requires qualified legal or regulatory review before publication. Jurisdiction: United States federal tobacco regulation. Controlling and agency sources were verified on August 8, 2026.
This guide provides general regulatory information, not legal advice. It describes the federal process and does not replace product-specific counsel.
PMTA in plain language
PMTA stands for premarket tobacco product application. The pathway comes from section 910 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 387j.
The statute generally treats a tobacco product as new when it was not commercially marketed in the United States as of February 15, 2007. A modification after that date can also create a new tobacco product.
Modern e-cigarettes commonly fall within these new-product rules. The application must address the exact product, not a loose brand family.
Product details can include the device, components, ingredients, design, labeling, and manufacturing information. Our guide to what is in vape juice explains some ingredient terms, but it is not a PMTA checklist.
The process at a glance
FDA describes several review stages on its PMTA overview page. The exact path and requests can depend on the application.
| Stage | Main question | What the stage does not mean |
|---|---|---|
| Submission | Did FDA receive an application? | The product is not authorized merely by submission |
| Acceptance review | Does the submission meet basic administrative requirements? | FDA has not reached the public health merits |
| Filing review | Is enough information present for substantive review? | Filing is not a marketing order |
| Application review | Does the evidence support the legal marketing standard? | Review activity is not permission to market |
| Action | Will FDA issue an MGO or MDO? | An MGO does not mean the product is safe |
| Postmarket phase | Are order conditions and reporting requirements met? | Authorization is not permanent immunity from action |
MGO means marketing granted order. MDO means marketing denial order.
Stage 1: Preparing the application
The applicant develops a product-specific evidence package. FDA's preparation and submission page describes the required structure.
Federal law and 21 C.F.R. Part 1114 govern PMTA content and procedures. Requirements can include:
- Full reports of information known or reasonably known about health risks.
- Product components, ingredients, additives, and properties.
- Principles of operation for the product.
- Manufacturing methods, facilities, and controls.
- Proposed labeling and required certifications.
- Environmental information or a basis for an exclusion.
- Samples or additional information when FDA requires them.
This work is much broader than sending a flavor name or laboratory result. The submission must let FDA evaluate the product and its likely effects at a population level.
Different nicotine sources do not remove the pathway. The synthetic versus tobacco-derived nicotine guide explains why federal coverage is not limited to tobacco-extracted nicotine.
Stage 2: Submission and receipt
An applicant sends the PMTA through an accepted route and identifies the products covered. FDA can acknowledge receipt and assign tracking information.
A receipt notice is procedural. It does not authorize sale and does not show that the application contains enough information for review.
This distinction matters when a package claims "PMTA submitted." The phrase describes an applicant's claimed step, not the agency's final action.
Stage 3: Acceptance review
FDA first checks threshold administrative issues. The agency can refuse to accept an application that does not meet basic requirements.
Acceptance allows the application to move forward. It does not mean FDA has agreed that marketing the product would be appropriate for the protection of public health.
A claimed acceptance letter should not be presented as a marketing order. Consumers checking a product should use the official workflow in Is This Vape Authorized by FDA?.
Stage 4: Filing review
FDA next determines whether the accepted application contains enough information for substantive review. A refuse-to-file action can stop an incomplete application at this stage.
Filing does not settle the merits. It means the agency can proceed with its detailed review based on the filed material.
Terms such as submitted, received, accepted, and filed describe different procedural points. None is a substitute for an MGO.
Stage 5: Substantive application review
The central legal standard is whether marketing the new tobacco product would be appropriate for the protection of the public health, often shortened to APPH.
Under 21 U.S.C. 387j, FDA considers risks and benefits to the population as a whole. That includes users and nonusers of tobacco products.
The statute directs attention to the likelihood that existing tobacco users will stop using those products. It also considers the likelihood that people who do not use tobacco will start.
This is a population standard, not a finding that the product is harmless to an individual. Evidence about product chemistry, toxicology, use behavior, youth initiation, and adult switching can all matter.
FDA may inspect manufacturing operations or request more information during review. An applicant must respond within the governing process and deadlines.
Device categories do not decide the result. A pod system and a disposable vape can present different evidence questions, but neither category receives automatic authorization.
Stage 6: Environmental review
Federal environmental requirements can apply to FDA actions. A PMTA includes environmental information or a claim of categorical exclusion when permitted.
The environmental analysis is separate from the core public health evidence, but it remains part of the agency's decision process. Missing or inadequate information can affect action on an application.
Stage 7: FDA action
After review, FDA can issue an MGO or an MDO for a product.
An MGO permits the specified product to be marketed subject to the order and applicable law. It does not authorize unnamed variations.
An MDO means FDA denied marketing authorization through that application. A product subject to an MDO cannot rely on that application as permission to market.
FDA publishes information about actions on its tobacco product marketing orders page. Public order documents can appear after the decision date.
Use accurate language:
- Say FDA authorized when a product has an applicable MGO.
- Do not say the tobacco product is FDA approved.
- Do not describe an application as authorization.
- Do not extend one order to other flavors, strengths, or models.
Stage 8: Postmarket requirements
An MGO is not the end of oversight. The order can require postmarket reporting, recordkeeping, and other controls.
The manufacturer must continue to follow the order and applicable tobacco requirements. Changes to the product may require further regulatory analysis or a new submission.
Federal law permits FDA to withdraw a marketing order on specified grounds. New evidence, order violations, or a change in the public health assessment can matter.
This is why current FDA records are more reliable than a permanent marketing claim on a package.
PMTA status terms compared
| Term | Practical meaning | Authorization to market? |
|---|---|---|
| Submitted | The applicant says it sent an application | No |
| Received | FDA records receipt | No |
| Accepted | Basic acceptance review passed | No |
| Filed | The application can enter substantive review | No |
| Under review | FDA is evaluating the application | No |
| MGO issued | FDA granted marketing for the named product | Yes, subject to the order and other law |
| MDO issued | FDA denied marketing through the application | No |
A pending application does not create an automatic safe harbor. Retail availability is also not proof of an MGO.
What a PMTA does not decide
A PMTA decision does not settle every legal question around a product.
State and local flavor restrictions, product directories, retailer licenses, taxes, and delivery rules may still apply. The state vape restrictions overview covers that separate layer.
An MGO also does not turn a tobacco product into a smoking-cessation medicine. Medical products follow different legal standards and indications.
Our vaping versus smoking evidence guide discusses comparative health evidence. A population-level FDA order should not be converted into a personal medical promise.
Common PMTA misunderstandings
"The whole brand is authorized"
Orders identify products. A company can have both authorized and unauthorized products under related branding.
"FDA reviewed it, so it is approved"
FDA explicitly distinguishes tobacco marketing authorization from product approval. An MGO is not a safety endorsement.
"A pending PMTA protects the product"
Pending status is not a marketing granted order. Enforcement posture and legal authorization are also different concepts.
"The nicotine level decides the outcome"
Nicotine strength is only one product attribute. Our nicotine strength chart explains label units, not the APPH decision.
"A later product can use an older order"
The exact identity and modifications matter. A new design, formulation, or labeling change can raise new-product questions.
A plain-language conclusion
The PMTA pathway moves from a product-specific application through acceptance, filing, substantive review, action, and postmarket oversight.
Only an applicable written marketing granted order supplies PMTA authorization. Submission, acceptance, filing, and pending status do not.
The order means FDA authorized marketing under the federal tobacco standard. It never means the vape is FDA approved or safe.